A novel multisite model to facilitate hepatitis C virus elimination in people experiencing homelessness

IF 9.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Adele Mourad , Rona McGeer , Emma Gray , Anna-Marie Bibby-Jones , Heather Gage , Lidia Salvaggio , Vikki Charles , Natasha Sanderson , Margaret O’Sullivan , Thomas Bird , Sumita Verma
{"title":"A novel multisite model to facilitate hepatitis C virus elimination in people experiencing homelessness","authors":"Adele Mourad ,&nbsp;Rona McGeer ,&nbsp;Emma Gray ,&nbsp;Anna-Marie Bibby-Jones ,&nbsp;Heather Gage ,&nbsp;Lidia Salvaggio ,&nbsp;Vikki Charles ,&nbsp;Natasha Sanderson ,&nbsp;Margaret O’Sullivan ,&nbsp;Thomas Bird ,&nbsp;Sumita Verma","doi":"10.1016/j.jhepr.2024.101183","DOIUrl":null,"url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Only a handful of countries are on target to achieve elimination of HCV by 2030. People experiencing homelessness (PEH) remain an important HCV reservoir. The END C study evaluated clinical, patient reported, and health economic outcomes of a decentralised integrated model.</div></div><div><h3>Methods</h3><div>This prospective study assessed a decentralised regional service based at multiple homeless sites in southeast England. Novel linkage-care strategies were used. We assessed generic and liver specific health-related quality of life (HRQoL) (SF-12v2; EQ-5D-5L, and SFLDQol) pre-/post-HCV treatment, and cost per HCV case detected and cured. The primary outcome was sustained virological response (SVR12) in the intention-to-treat (ITT) population.</div></div><div><h3>Results</h3><div>We recruited 418 individuals with mean age 44.45 ± 10.6 years, 78% were male, 74% were currently homeless, current injecting drug use or alcohol use was 25% and 65%, respectively. Prevalence of cirrhosis (liver stiffness measurement ≥12 kPa) was 12%. A total of 28% (n = 116) were HCV PCR-positive of whom 105 individuals received direct acting antiviral treatment. The ITT SVR12 rates were 81% (95% CI 72%–88%), the only predictor of SVR12 was &gt;80% treatment adherence (OR 20.69, 95% CI 6.227–68.772, <em>p &lt;</em>0.001). HRQoL improved significantly after SVR12: SF-12v2 (General Health, Mental Health, Social Functioning, Mental Health Composite Score <em>p &lt;</em>0.049); SFLDQoL (Symptoms/Effects of Liver Disease, Distress, Loneliness <em>p &lt;</em>0.004) and EQ-5D-5L (Index Score, Visual Analog Scale <em>p &lt;</em>0.001). Costs (British pound 2022) per HCV case detected and per case cured were £359 and £257, respectively. Reinfection rates were 6.82/100 person years.</div></div><div><h3>Conclusion</h3><div>The END C study endorses a multisite decentralised service for PEH enabling excellent linkage to care, high SVR12 rates, and significant improvements in generic and liver specific HRQoL, all being achieved at modest costs. Such services are paramount to help achieve HCV elimination.</div></div><div><h3>Impact and implications:</h3><div>In people experiencing homeless, we found a high prevalence of HCV, alcohol, and substance misuse including overdoses and mental health issues. Despite this, an integrated and decentralised service resulted in excellent linkage to care with high SVR12 rates. Even in this complex cohort with multiple comorbidities, SVR12 was associated with significant improvements in both generic and liver specific HRQoL. This was all achieved at modest costs in a community setting. Such models of care are feasible, easy to replicate, and essential if we are to achieve HCV elimination.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 11","pages":"Article 101183"},"PeriodicalIF":9.5000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JHEP Reports","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589555924001873","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background & Aims

Only a handful of countries are on target to achieve elimination of HCV by 2030. People experiencing homelessness (PEH) remain an important HCV reservoir. The END C study evaluated clinical, patient reported, and health economic outcomes of a decentralised integrated model.

Methods

This prospective study assessed a decentralised regional service based at multiple homeless sites in southeast England. Novel linkage-care strategies were used. We assessed generic and liver specific health-related quality of life (HRQoL) (SF-12v2; EQ-5D-5L, and SFLDQol) pre-/post-HCV treatment, and cost per HCV case detected and cured. The primary outcome was sustained virological response (SVR12) in the intention-to-treat (ITT) population.

Results

We recruited 418 individuals with mean age 44.45 ± 10.6 years, 78% were male, 74% were currently homeless, current injecting drug use or alcohol use was 25% and 65%, respectively. Prevalence of cirrhosis (liver stiffness measurement ≥12 kPa) was 12%. A total of 28% (n = 116) were HCV PCR-positive of whom 105 individuals received direct acting antiviral treatment. The ITT SVR12 rates were 81% (95% CI 72%–88%), the only predictor of SVR12 was >80% treatment adherence (OR 20.69, 95% CI 6.227–68.772, p <0.001). HRQoL improved significantly after SVR12: SF-12v2 (General Health, Mental Health, Social Functioning, Mental Health Composite Score p <0.049); SFLDQoL (Symptoms/Effects of Liver Disease, Distress, Loneliness p <0.004) and EQ-5D-5L (Index Score, Visual Analog Scale p <0.001). Costs (British pound 2022) per HCV case detected and per case cured were £359 and £257, respectively. Reinfection rates were 6.82/100 person years.

Conclusion

The END C study endorses a multisite decentralised service for PEH enabling excellent linkage to care, high SVR12 rates, and significant improvements in generic and liver specific HRQoL, all being achieved at modest costs. Such services are paramount to help achieve HCV elimination.

Impact and implications:

In people experiencing homeless, we found a high prevalence of HCV, alcohol, and substance misuse including overdoses and mental health issues. Despite this, an integrated and decentralised service resulted in excellent linkage to care with high SVR12 rates. Even in this complex cohort with multiple comorbidities, SVR12 was associated with significant improvements in both generic and liver specific HRQoL. This was all achieved at modest costs in a community setting. Such models of care are feasible, easy to replicate, and essential if we are to achieve HCV elimination.

Abstract Image

促进在无家可归者中消除丙型肝炎病毒的新型多站点模式
背景& 目的只有少数几个国家正在努力实现到 2030 年消除丙型肝炎病毒的目标。无家可归者(PEH)仍是重要的丙型肝炎病毒库。END C研究评估了分散式综合模式的临床、患者报告和卫生经济效益。方法这项前瞻性研究评估了英格兰东南部多个无家可归者营地的分散式区域服务。我们采用了新颖的联系-护理策略。我们评估了HCV治疗前后的一般和肝脏特异性健康相关生活质量(HRQoL)(SF-12v2、EQ-5D-5L和SFLDQol),以及每个HCV病例的检测和治愈成本。主要结果是意向治疗(ITT)人群的持续病毒学应答(SVR12)。结果我们招募了 418 人,平均年龄(44.45 ± 10.6)岁,78% 为男性,74% 目前无家可归,目前注射毒品或酗酒的比例分别为 25% 和 65%。肝硬化(肝硬度测量值≥12 kPa)患病率为 12%。共有 28% 的患者(n = 116)HCV PCR 阳性,其中 105 人接受了直接作用抗病毒治疗。ITT SVR12率为81%(95% CI 72%-88%),SVR12的唯一预测因素是80%的治疗依从性(OR 20.69,95% CI 6.227-68.772,p <0.001)。SVR12 后 HRQoL 明显改善:SF-12v2(一般健康、心理健康、社会功能、心理健康综合评分 p <0.049);SFLDQoL(肝病症状/影响、苦恼、孤独 p <0.004)和 EQ-5D-5L(指数评分、视觉模拟量表 p <0.001)。发现每例 HCV 病例和治愈每例 HCV 病例的成本(2022 英镑)分别为 359 英镑和 257 英镑。结论END C研究认可了针对PEH的多站点分散式服务,这种服务能够实现良好的护理连接、较高的SVR12率以及一般和肝脏特异性HRQoL的显著改善,所有这些都是以适中的成本实现的。影响和意义:我们发现,在无家可归者中,HCV、酗酒、药物滥用(包括用药过量)和心理健康问题的发病率很高。尽管如此,综合分散的服务仍为他们提供了很好的治疗衔接,SVR12率也很高。即使在这个具有多种并发症的复杂群体中,SVR12 也能显著改善一般和肝脏特定的 HRQoL。这一切都是在社区环境下以适度的成本实现的。这种护理模式是可行的、易于推广的,也是我们实现根除丙型肝炎病毒的关键。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JHEP Reports
JHEP Reports GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
12.40
自引率
2.40%
发文量
161
审稿时长
36 days
期刊介绍: JHEP Reports is an open access journal that is affiliated with the European Association for the Study of the Liver (EASL). It serves as a companion journal to the highly respected Journal of Hepatology. The primary objective of JHEP Reports is to publish original papers and reviews that contribute to the advancement of knowledge in the field of liver diseases. The journal covers a wide range of topics, including basic, translational, and clinical research. It also focuses on global issues in hepatology, with particular emphasis on areas such as clinical trials, novel diagnostics, precision medicine and therapeutics, cancer research, cellular and molecular studies, artificial intelligence, microbiome research, epidemiology, and cutting-edge technologies. In summary, JHEP Reports is dedicated to promoting scientific discoveries and innovations in liver diseases through the publication of high-quality research papers and reviews covering various aspects of hepatology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信